157 related articles for article (PubMed ID: 38570455)
1. Affinity Measurement of Non-covalent Interactions of the Covalent KRAS G12C GDP Inhibitor MRTX849 to RAS Isoforms Using Surface Plasmon Resonance.
Alexander P; Stephen AG
Methods Mol Biol; 2024; 2797():103-114. PubMed ID: 38570455
[TBL] [Abstract][Full Text] [Related]
2. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
3. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
[TBL] [Abstract][Full Text] [Related]
5. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
[TBL] [Abstract][Full Text] [Related]
6. The KRAS
Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
[TBL] [Abstract][Full Text] [Related]
7. KRAS G12C fragment screening renders new binding pockets.
Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
[TBL] [Abstract][Full Text] [Related]
8. The KRAS-G12C inhibitor: activity and resistance.
Liu J; Kang R; Tang D
Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of
Chen CY; Lu Z; Scattolin T; Chen C; Gan Y; McLaughlin M
Org Lett; 2023 Feb; 25(6):944-949. PubMed ID: 36723667
[TBL] [Abstract][Full Text] [Related]
10. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
12. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
13. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the GTPase KRAS
Xu Q; Zhang G; Liu Q; Li S; Zhang Y
Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
17. Activity and resistance to KRAS
Ye W; Lu X; Qiao Y; Ou WB
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
[TBL] [Abstract][Full Text] [Related]
18. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J; Tímár J
Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
[TBL] [Abstract][Full Text] [Related]
19. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
20. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
